Literature DB >> 17021308

Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele.

Mona Anand, Jamshid Khorashad, David Marin, Jane F Apperley, John M Goldman, Jaspal Singh Kaeda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17021308     DOI： 10.1182/blood-2006-05-020859

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  2 in total

1.  Nilotinib rapidly reverses breakpoint cluster region-Abelson oncogene fusion gene and M244V mutations in a patient with chronic myelogenous leukemia: A case report.

Authors:  Xuliang Shen; Meixiang Zhang; Yifan Shen; Wenzhi Shi; Wei Liu; W U Wei
Journal:  Exp Ther Med       Date:  2015-08-24       Impact factor: 2.447

2.  Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia.

Authors:  Vladimir Vainstein; Christopher A Eide; Thomas O'Hare; Ofir Shukron; Brian J Druker
Journal:  Blood       Date:  2013-09-23       Impact factor: 22.113
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.